The company will use the investment to further its radar-based monitoring application technology. Xandar’s system received FDA clearance, according to a Feb. 27 Portfolia news release shared with Becker’s.
Portfolia participated in the company’s $10 million series A financing round. The financial terms of this investment were not disclosed.
“Our radar-based solutions represent the future of healthcare and patient monitoring, opening countless doors for healthcare providers and enabling people everywhere to achieve a new standard of quality in the predictive and preventive care they receive,” Sam Yang, founder and CEO of Xandar Kardian, said in the release. “Portfolia’s continued support of Xandar Kardian, highlighted by this significant investment, speaks volumes about how much they align with our mission and believe in the life-saving capabilities of our technology.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
